

Alessandro Isidori

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5135630/publications.pdf>

Version: 2024-02-01

145
papers

3,433
citations

159585

30
h-index

161849

54
g-index

149
all docs

149
docs citations

149
times ranked

4698
citing authors

#	ARTICLE	IF	CITATIONS
1	Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25 ^{hi} into CD25 ⁺ T regulatory cells. <i>Blood</i> , 2007, 109, 2871-2877.	1.4	357
2	Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. <i>Blood</i> , 2011, 118, 3273-3279.	1.4	356
3	Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state. <i>Blood</i> , 2002, 99, 443-449.	1.4	133
4	Nucleofection Is an Efficient Nonviral Transfection Technique for Human Bone Marrow-Derived Mesenchymal Stem Cells. <i>Stem Cells</i> , 2006, 24, 454-461.	3.2	123
5	BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. <i>Blood</i> , 2011, 118, 3419-3425.	1.4	123
6	Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis. <i>Cancer</i> , 2020, 126, 1243-1252.	4.1	106
7	Acute myeloid leukemia cells constitutively express the immunoregulatory enzyme indoleamine 2,3-dioxygenase. <i>Leukemia</i> , 2007, 21, 353-355.	7.2	99
8	BCR-ABL Independent Mechanisms of Resistance in Chronic Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2019, 9, 939.	2.8	83
9	Differences among young adults, adults and elderly chronic myeloid leukemia patients. <i>Annals of Oncology</i> , 2015, 26, 185-192.	1.2	72
10	Gemtuzumab Ozogamicin for Relapsed and Refractory Acute Myeloid Leukemia and Myeloid Sarcomas. <i>Leukemia and Lymphoma</i> , 2004, 45, 1791-1795.	1.3	67
11	The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia – analysis of 848 patients. <i>Leukemia</i> , 2001, 15, 903-909.	7.2	65
12	Immunotherapy in Acute Myeloid Leukemia: Where We Stand. <i>Frontiers in Oncology</i> , 2021, 11, 656218.	2.8	63
13	The role of the immunosuppressive microenvironment in acute myeloid leukemia development and treatment. <i>Expert Review of Hematology</i> , 2014, 7, 807-818.	2.2	62
14	Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients. <i>Haematologica</i> , 2005, 90, 225-31.	3.5	62
15	Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia. A pilot study. <i>Leukemia</i> , 2002, 16, 1609-1614.	7.2	54
16	Stem cell mobilization and collection in patients with liver cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 27, 932-939.	3.7	52
17	R-COMP 21 for frail elderly patients with aggressive B-cell non-Hodgkin lymphoma: A pilot study. <i>Leukemia and Lymphoma</i> , 2008, 49, 1081-1086.	1.3	52
18	Tailored Therapy in an Unselected Population of 91 Elderly Patients with DLBCL Prospectively Evaluated Using a Simplified CGA. <i>Oncologist</i> , 2012, 17, 663-672.	3.7	52

#	ARTICLE	IF	CITATIONS
19	Venetoclax-Based Combinations in Acute Myeloid Leukemia: Current Evidence and Future Directions. <i>Frontiers in Oncology</i> , 2020, 10, 562558.	2.8	49
20	Iron toxicity – Its effect on the bone marrow. <i>Blood Reviews</i> , 2018, 32, 473-479.	5.7	46
21	Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients. <i>Hematological Oncology</i> , 2018, 36, 561-569.	1.7	46
22	Interleukin-12 production by leukemia-derived dendritic cells counteracts the inhibitory effect of leukemic microenvironment on T cells. <i>Experimental Hematology</i> , 2005, 33, 1521-1530.	0.4	44
23	Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis. <i>Blood Cancer Journal</i> , 2021, 11, 4.	6.2	41
24	Generation of Dendritic Cells from Positively Selected CD14 ⁺ Monocytes for Anti-tumor Immunotherapy. <i>Leukemia and Lymphoma</i> , 2004, 45, 1419-1428.	1.3	40
25	Bendamustine, etoposide, cytarabine, melphalan, and autologous stem cell rescue produce a 72% 3-year PFS in resistant lymphoma. <i>Blood</i> , 2014, 124, 3029-3031.	1.4	40
26	Imatinib in Very Elderly Patients with Chronic Myeloid Leukemia in Chronic Phase: A Retrospective Study. <i>Drugs and Aging</i> , 2013, 30, 629-637.	2.7	36
27	Novel regimens prior to autologous stem cell transplantation for the management of adults with relapsed/refractory non-Hodgkin lymphoma and Hodgkin lymphoma: alternatives to BEAM conditioning. <i>Leukemia and Lymphoma</i> , 2016, 57, 2499-2509.	1.3	36
28	Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia. <i>Leukemia</i> , 2001, 15, 764-771.	7.2	35
29	Autologous transplantation of granulocyte colony-stimulating factor-primed bone marrow is effective in supporting myeloablative chemotherapy in patients with hematologic malignancies and poor peripheral blood stem cell mobilization. <i>Blood</i> , 2003, 102, 1595-1600.	1.4	33
30	Technetium-99m sestamibi scintigraphy is sensitive and specific for the staging and the follow-up of patients with multiple myeloma: a multicentre study on 397 scans. <i>British Journal of Haematology</i> , 2007, 136, 729-735.	2.5	32
31	Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice. <i>Annals of Hematology</i> , 2018, 97, 1577-1580.	1.8	32
32	Second chronic phase before transplantation is crucial for improving survival of blastic phase chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 2000, 109, 722-728.	2.5	30
33	Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival. <i>Leukemia Research</i> , 2014, 38, 1173-1176.	0.8	30
34	The Yin and Yang of the Bone Marrow Microenvironment: Pros and Cons of Mesenchymal Stromal Cells in Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2019, 9, 1135.	2.8	30
35	Efficacy and safety of ruxolitinib in intermediate-IPSS risk myelofibrosis patients: Results from an independent study. <i>Hematological Oncology</i> , 2018, 36, 285-290.	1.7	29
36	Persistent Immune Stimulation Exacerbates Genetically Driven Myeloproliferative Disorders via Stromal Remodeling. <i>Cancer Research</i> , 2017, 77, 3685-3699.	0.9	27

#	ARTICLE	IF	CITATIONS
37	Deferasirox improves hematopoiesis after allogeneic hematopoietic SCT. <i>Bone Marrow Transplantation</i> , 2014, 49, 585-587.	2.4	26
38	Management of Patients With Hematologic Malignancies During the COVID-19 Pandemic: Practical Considerations and Lessons to Be Learned. <i>Frontiers in Oncology</i> , 2020, 10, 1439.	2.8	26
39	Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study. <i>Seminars in Hematology</i> , 2018, 55, 248-255.	3.4	24
40	Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome. <i>Oncotarget</i> , 2016, 7, 80083-80090.	1.8	24
41	All-trans retinoic acid significantly reduces the incidence of early hemorrhagic death during induction therapy of acute promyelocytic leukemia. <i>European Journal of Haematology</i> , 2000, 64, 139-144.	2.2	23
42	Positive Selection and Transplantation of Autologous Highly Purified CD133+ Stem Cells in Resistant/Relapsed Chronic Lymphocytic Leukemia Patients Results in Rapid Hematopoietic Reconstitution without an Adequate Leukemic Cell Purging. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 1224-1232.	2.0	23
43	Alternative novel therapies for the treatment of elderly acute myeloid leukemia patients. <i>Expert Review of Hematology</i> , 2013, 6, 767-784.	2.2	23
44	Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients. <i>Leukemia Research</i> , 2018, 74, 86-88.	0.8	23
45	Chemotherapy-Induced Tumor Cell Death at the Crossroads Between Immunogenicity and Immunotolerance: Focus on Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2019, 9, 1004.	2.8	23
46	Second primary malignancy in myelofibrosis patients treated with ruxolitinib. <i>British Journal of Haematology</i> , 2021, 193, 356-368.	2.5	19
47	Low Dose Ara-C for Myelodysplastic Syndromes: is it Still a Current Therapy?. <i>Leukemia and Lymphoma</i> , 2004, 45, 1531-1538.	1.3	18
48	High-dose therapy followed by stem cell transplantation in Hodgkin's lymphoma: past and future. <i>Expert Review of Hematology</i> , 2013, 6, 451-464.	2.2	17
49	Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontline. <i>Annals of Hematology</i> , 2019, 98, 2329-2338.	1.8	17
50	Nonpegylated liposomal doxorubicin in the treatment of B-cell non-Hodgkin's lymphoma: where we stand. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 357-363.	2.4	16
51	Environmental nanoparticles are significantly over-expressed in acute myeloid leukemia. <i>Leukemia Research</i> , 2016, 50, 50-56.	0.8	16
52	Iron Toxicity and Chelation Therapy in Hematopoietic Stem Cell Transplant. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 371-379.	1.2	16
53	Low-dose lenalidomide plus cytarabine in very elderly, unfit acute myeloid leukemia patients: Final result of a phase II study. <i>Leukemia Research</i> , 2017, 62, 77-83.	0.8	15
54	Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data. <i>Hematological Oncology</i> , 2020, 38, 372-380.	1.7	15

#	ARTICLE	IF	CITATIONS
55	Cyclophosphamide, pegylated liposomal doxorubicin, vincristine and prednisone (CDOP) plus rituximab is effective and well tolerated in poor performance status elderly patients with non-Hodgkin's lymphoma. <i>Leukemia and Lymphoma</i> , 2005, 46, 477-479.	1.3	14
56	All-trans retinoic acid at low concentration directly stimulates normal adult megakaryocytopoiesis in the presence of thrombopoietin or combined cytokines. <i>European Journal of Haematology</i> , 1999, 63, 149-153.	2.2	14
57	The <i>hOCT1</i> and <i>ABCB1</i> polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia. <i>Oncotarget</i> , 2017, 8, 88021-88033.	1.8	14
58	Efficacy of dasatinib in conjunction with \pm -interferon for the treatment of imatinib-resistant and dasatinib-resistant Ph+ acute lymphoblastic leukemia. <i>Leukemia</i> , 2009, 23, 1687-1688.	7.2	13
59	Dasatinib, even at low doses, is an effective second-line therapy for chronic myeloid leukemia patients resistant or intolerant to imatinib. Results from a real life-based Italian multicenter retrospective study on 114 patients. <i>American Journal of Hematology</i> , 2010, 85, 960-963.	4.1	13
60	Nanomedicine strategies for hematological malignancies: what is next?. <i>Nanomedicine</i> , 2014, 9, 2415-2428.	3.3	13
61	Low-dose lenalidomide plus cytarabine induce complete remission that can be predicted by genetic profiling in elderly acute myeloid leukemia patients. <i>Leukemia</i> , 2014, 28, 967-970.	7.2	13
62	Liposomal daunorubicin (DaunoXome) for treatment of relapsed meningeal acute myeloid leukemia. <i>Leukemia</i> , 2002, 16, 1880-1881.	7.2	12
63	Efficacy of imatinib mesylate (ST1571) in conjunction with alpha-interferon: long-term quantitative molecular remission in relapsed P-190BCR-ABL-positive acute lymphoblastic leukemia. <i>Leukemia</i> , 2002, 16, 2159-2160.	7.2	12
64	Consolidation therapy for adult acute myeloid leukemia: A systematic analysis according to evidence based medicine. <i>Leukemia and Lymphoma</i> , 2006, 47, 1091-1102.	1.3	12
65	The incidence of pleural and pericardial effusion is not higher in patients receiving dasatinib at low doses. (Reply). <i>Haematologica</i> , 2011, 96, e23-e24.	3.5	12
66	Doxorubicin variants for hematological malignancies. <i>Nanomedicine</i> , 2011, 6, 303-306.	3.3	11
67	Caring for AML Patients During the COVID-19 Crisis: An American and Italian Experience. <i>Frontiers in Oncology</i> , 2020, 10, 1689.	2.8	11
68	Outcome of Patients with Myelofibrosis after Ruxolitinib Failure: Role of Disease Status and Treatment Strategies in 214 Patients. <i>Blood</i> , 2018, 132, 4277-4277.	1.4	11
69	Sequential combination of thalidomide and erythropoietin determines transfusion independence and disease control in idiopathic myelofibrosis previously insensitive to both drugs used as single agents. <i>Leukemia</i> , 2003, 17, 1669-1670.	7.2	10
70	An observational study of once weekly intravenous ganciclovir as CMV prophylaxis in heavily pre-treated chronic lymphocytic leukemia patients receiving subcutaneous alemtuzumab. <i>Leukemia and Lymphoma</i> , 2006, 47, 2542-2546.	1.3	10
71	Genetic profiling in acute myeloid leukemia: a path to predicting treatment outcome. <i>Expert Review of Hematology</i> , 2018, 11, 455-461.	2.2	10
72	High-dose Benda-EAM versus BEAM in patients with relapsed/refractory classical Hodgkin lymphoma undergoing autologous stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 481-484.	2.4	10

#	ARTICLE	IF	CITATIONS
73	Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib. <i>Annals of Hematology</i> , 2019, 98, 889-896.	1.8	10
74	Clinical Relevance of ABCB1, ABCG2, and ABCC2 Gene Polymorphisms in Chronic Myeloid Leukemia Patients Treated With Nilotinib. <i>Frontiers in Oncology</i> , 2021, 11, 672287.	2.8	10
75	A Novel High Dose Chemotherapy Strategy with Bendamustine In Adjunct to Etoposide, Cytarabine and Melphalan (BeEAM) Followed by Autologous Stem Cell Rescue Is Safe and Highly Effective for the Treatment of Resistant/Relapsed Lymphoma Patients: a Phase I-II Study on 44 Patients. <i>Blood</i> , 2010, 116, 31-31.	1.4	10
76	Genomic profiling and predicting treatment response in acute myeloid leukemia. <i>Pharmacogenomics</i> , 2019, 20, 467-470.	1.3	9
77	Chemotherapy of Secondary Leukemias. <i>Leukemia and Lymphoma</i> , 2000, 37, 543-549.	1.3	8
78	Molecular monitoring of acute myeloid leukemia associated with inv(16): threshold of CBFÎ²/MYH11 transcript copy number above which relapse occurs and below which continuous Complete Remission is likely. <i>Leukemia</i> , 2003, 17, 650-651.	7.2	8
79	Long-term molecular complete remission with IFN-Î± in Ph+ adult acute lymphoid leukemia patients. <i>Leukemia</i> , 2008, 22, 1617-1618.	7.2	8
80	Resistant chronic myeloid leukemia beyond tyrosine-kinase inhibitor therapy: which role for omacetaxine?. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 1-3.	1.8	8
81	Immunosenescence and Immunotherapy in Elderly Acute Myeloid Leukemia Patients: Time for a Biology-Driven Approach. <i>Cancers</i> , 2018, 10, 211.	3.7	8
82	Double reinforcement with fludarabine/high-dose cytarabine enhances the impact of autologous stem cell transplantation in acute myeloid leukemia patients. <i>Bone Marrow Transplantation</i> , 2001, 27, 829-835.	2.4	7
83	Efficacy and safety of second-line ponatinib after failure of a single previous tyrosine kinase inhibitor for chronic myeloid leukemia patients in chronic phase. <i>Haematologica</i> , 2016, 101, e267-e268.	3.5	7
84	Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients. <i>British Journal of Haematology</i> , 2018, 183, 35-46.	2.5	7
85	Dendritic Cell Differentiation. <i>Journal of Immunology</i> , 2004, 172, 3-4.	0.8	6
86	AUTOLOGOUS STEM CELL TRANSPLANTATION FOR AGGRESSIVE LYMPHOMAS. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2012, 4, e2012075.	1.3	6
87	UPDATE ON THE ROLE OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2012, 4, e2012069.	1.3	6
88	Editorial: The Biological Landscape of Immunotherapy in AML. <i>Frontiers in Oncology</i> , 2021, 11, 671252.	2.8	6
89	Interleukin-12 Gene Expression into Acute Myeloid Leukemia-Derived Dendritic Cells Overcomes T-Cell Functional Impairment Induced by Leukemic Microenvironment.. <i>Blood</i> , 2004, 104, 1816-1816.	1.4	6
90	Advancement in high dose therapy and autologous stem cell rescue in lymphoma. <i>World Journal of Stem Cells</i> , 2015, 7, 1039-46.	2.8	6

#	ARTICLE	IF	CITATIONS
91	Autologous stem cell transplantation for acute myeloid leukemia patients in first complete remission: a 10-year follow-up study of 118 patients. <i>Haematologica</i> , 2005, 90, 139-41.	3.5	6
92	SNPs Array Karyotyping Reveals a Novel Recurrent 20p13 Amplification in Primary Myelofibrosis. <i>PLoS ONE</i> , 2011, 6, e27560.	2.5	5
93	The incidence of <i>Pneumocystis jirovecii</i> pneumonia is not higher in patients receiving dose-dense therapy with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine, and prednisolone and adequate <i>Pneumocystis jirovecii</i> pneumonia prophylaxis. <i>Leukemia and Lymphoma</i> , 2011, 52, 148-149.	1.3	5
94	Complete Clearance of Ph+ Metaphases after 3 Months Is a Very Early Indicator of Good Response to Imatinib as Front-Line Treatment in Chronic Myelogenous Leukemia. <i>Acta Haematologica</i> , 2013, 129, 126-134.	1.4	5
95	Microdose $\hat{\pm}$ -interferon shows clinical and antiangiogenic effect in extramedullary myeloid tumor: a case report. <i>Leukemia</i> , 2003, 17, 986-987.	7.2	4
96	Mini-ICE effectively mobilises peripheral blood stem cells after fludarabine-based regimens in acute myeloid leukaemia. <i>European Journal of Haematology</i> , 2005, 74, 277-281.	2.2	4
97	Radioimmunotherapy-based conditioning regimen prior to autologous stem cell transplantation in non-Hodgkin lymphoma. <i>International Journal of Hematologic Oncology</i> , 2018, 7, IJH01.	1.6	4
98	Gene expression profile predicts response to the combination of tosedostat and low-dose cytarabine in elderly AML. <i>Blood Advances</i> , 2020, 4, 5040-5049.	5.2	4
99	Benda-BEAM High-Dose Therapy Prior to Auto-SCT Is Effective in Resistant/Relapsed DLBCL. <i>Blood</i> , 2015, 126, 1999-1999.	1.4	4
100	No Preferential Sensitivity of t(8;21) Acute Myeloid Leukemias to Cytosine Arabinoside in Vitro: Is Intensity of Therapy or High Dose Ara-C Crucial for Response?. <i>Leukemia and Lymphoma</i> , 2004, 45, 1361-1364.	1.3	3
101	AML therapy in the elderly: a time for a change. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 891-892.	2.4	3
102	Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib. <i>Hematological Oncology</i> , 2019, 37, 418-423.	1.7	3
103	Severe Acute Respiratory Syndrome Coronavirus-2 Pandemia: Facts and Perspectives in a Bone Marrow Transplant Unit. <i>Frontiers in Oncology</i> , 2020, 10, 1626.	2.8	3
104	Safety and Efficacy of Bendamustine with or without Rituximab for the Treatment of Heavily Pretreated CLL and Lymphoma Patients. A Multicenter Retrospective Study.. <i>Blood</i> , 2009, 114, 1662-1662.	1.4	3
105	Prognostic Role of Neutrophil to Lymphocyte Ratio (NLR) in Myelofibrosis Patients Treated with Ruxolitinib: A Multi-Center Experience. <i>Blood</i> , 2018, 132, 4303-4303.	1.4	3
106	<sc>PBSC</sc> mobilization in patients with autoimmune diseases: what's next. <i>European Journal of Haematology</i> , 2016, 97, 5-6.	2.2	2
107	MTHFR, TS and XRCC1 genetic variants may affect survival in patients with myelodysplastic syndromes treated with supportive care or azacitidine. <i>Pharmacogenomics Journal</i> , 2018, 18, 444-449.	2.0	2
108	Benda-BEAM prior to ASCT and renal toxicity: Much ado about nothing. <i>American Journal of Hematology</i> , 2019, 94, E104-E105.	4.1	2

#	ARTICLE	IF	CITATIONS
109	Tosedostat Plus Low Dose Cytarabine Induces a High Rate of Responses That Can be Predicted By Genetic Profiling in Elderly AML. <i>Blood</i> , 2015, 126, 329-329.	1.4	2
110	Renewing the immunological approach to AML treatment: from novel pathways to innovative therapies. <i>Cancer Research Frontiers</i> , 2016, 2, 226-251.	0.2	2
111	The prevention of alemtuzumab-induced cytomegalovirus reactivation: still a matter of debate. An update from Pesaro experience with once weekly intravenous ganciclovir. <i>Leukemia and Lymphoma</i> , 2009, 50, 294-296.	1.3	1
112	Myeloid Sarcoma: The Clinician's Point of View. <i>Leukemia Research and Treatment</i> , 2011, 2011, 1-2.	2.0	1
113	Stem Cell Mobilization: An Overview. , 2012, , 51-60.		1
114	Conditioning regimens in acute myeloid leukemia. <i>Expert Review of Hematology</i> , 2014, 7, 465-479.	2.2	1
115	XRCC1 399GG genotype predicts significantly longer overall survival in resistant lymphoma patients treated with Benda-EAM and ASCT. <i>Bone Marrow Transplantation</i> , 2020, 55, 818-820.	2.4	1
116	SARS-CoV-2 impact in a community-based hematological ward in an Italian Red Zone. <i>Annals of Hematology</i> , 2020, 99, 1677-1678.	1.8	1
117	One Size Does Not Fit to All: Intolerant or Resistant CML Patients Could Benefit from Different Ponatinib Starting Dose Strategies. Multicenter Italian Experience. <i>Blood</i> , 2018, 132, 1732-1732.	1.4	1
118	ENL YEATS domain: targeting the acute myeloid leukemia epigenome. <i>Biotarget</i> , 0, 2, 12-12.	0.5	1
119	Bendamustine, Etoposide, Cytarabine and Melphalan (BeEAM) Followed By Autologous Stem Cell Transplantation Produce a 3-Year Progression-Free Survival Of 75% In Heavily Pre-Treated Hodgkin and Non-Hodgkin Lymphoma. <i>Blood</i> , 2013, 122, 2134-2134.	1.4	1
120	A diagnostic dilemma in stem cell transplantation for β^2 -Thalassemia major: progressive loss of take or pure red cell aplasia?. <i>International Journal of Hematology</i> , 2007, 86, 461-462.	1.6	0
121	editorial comment: Stem cell mobilization: the other side of the coin. <i>British Journal of Haematology</i> , 2010, 150, 663-664.	2.5	0
122	Clinical Experience with Liposomal Doxorubicin. <i>Frontiers in Nanobiomedical Research</i> , 2014, , 501-540.	0.1	0
123	Nanocarriers targeting cancer stem cells: how to help drugs to find their way home. <i>Nanomedicine</i> , 2015, 10, 1043-1046.	3.3	0
124	251 TS, MTHFR AND XRCC1 GENETIC VARIANTS INFLUENCE THE OUTCOME OF MDS PATIENTS IRRESPECTIVELY OF IPSS RISK. <i>Leukemia Research</i> , 2015, 39, S125.	0.8	0
125	Benda-BEAM High-Dose Therapy Prior to Auto-SCT is Effective in Resistant/Relapsed DLBCL. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S38.	2.0	0
126	Enteric-coated mycophenolate sodium: a new option for GVHD prophylaxis?. <i>European Journal of Haematology</i> , 2017, 98, 320-321.	2.2	0

#	ARTICLE	IF	CITATIONS
127	Efficacy and Toxicity of FLAI vs ICE for Induction Treatment of Newly Diagnosed AML Patients, Younger Than 60 Years.. Blood, 2004, 104, 878-878.	1.4	0
128	Purification of Allogeneic Idiotype-Specific T Lymphocytes According to IFN- β Production for Adoptive Immunotherapy in Multiple Myeloma Patients.. Blood, 2004, 104, 2119-2119.	1.4	0
129	R-COMP 21 (Prednisone, Cyclophosphamide, Vincristine, Myocettm and Rituximab) for Frail and Elderly Patients with Aggressive B-Cell Non-Hodgkin Lymphoma: A Pilot Study.. Blood, 2007, 110, 4442-4442.	1.4	0
130	Identification of Novel Cryptic Chromosomal Abnormalities in Primary Myelofibrosis by Single-Nucleotide Polymorphism Oligonucleotide Microarray.. Blood, 2009, 114, 1890-1890.	1.4	0
131	Adoptive Immunotherapy with Haploidentical Kir Ligand-Mismatched Natural Killer Cells In Elderly High Risk Acute Myeloid Leukemia Patients: Biological and Clinical Results of A Pilot Study. Blood, 2010, 116, 4287-4287.	1.4	0
132	LOW-DOSE LENALIDOMIDE COUPLED with LOW-DOSE Cytarabine INDUCES COMPLETE REMISSION of Elderly ACUTE Myeloid LEUKEMIA PATIENTS with Unfavorable Citogenetics: PRELIMINARY RESULTS of A PHASE II STUDY,. Blood, 2011, 118, 3627-3627.	1.4	0
133	Low-Dose Lenalidomide Plus Low Dose Cytarabine Induce Complete Remission That Can Be Predicted By Genetic Profiling In Very Elderly Acute Myeloid Leukemia Patients. Blood, 2013, 122, 496-496.	1.4	0
134	The Mutational Status Of Genes Involved In DNA Repair and Folate Pathway Predicts Overall Survival Of Patients With Low-Risk, Untreated Myelodysplastic Syndrome. Blood, 2013, 122, 2815-2815.	1.4	0
135	Deep Molecular Response to Nilotinib As First-Line Treatment of BCR-ABL+ CML in Early Chronic Phase: A Phase 3b Multicenter Study of the Gimema CML Working Party. Blood, 2014, 124, 4532-4532.	1.4	0
136	Environmental Nanoparticles Are Significantly over-Expressed in Acute Myeloid Leukemia: a Novel Pathogenetic Cofactor?. Blood, 2015, 126, 4965-4965.	1.4	0
137	Prognostic Impact of TS, MTHFR and XRCC1 Genetic Variants in 113 Patients with Myelodysplastic Syndromes. Blood, 2015, 126, 1675-1675.	1.4	0
138	Very Elderly Patients with Chronic Phase-Chronic Myeloid Leukemia on Imatinib: No Impact of Concomitant Drugs on Complete Cytogenetic Response. Blood, 2015, 126, 1582-1582.	1.4	0
139	Prospective Metabolic and Cardiovascular Assessment in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Nilotinib 300 Mg Bid Frontline in the Gimema 0811 Trial. Blood, 2015, 126, 4046-4046.	1.4	0
140	Long-Term Follow-up in Very Elderly Patients with Chronic Myeloid Leukemia Treated with Imatinib Frontline. Blood, 2015, 126, 1598-1598.	1.4	0
141	Young CML Patients Treated Frontline with Imatinib or Second Generation TKIs: Clinical Characteristics and Outcome. Blood, 2016, 128, 3078-3078.	1.4	0
142	The hOCT1 and ABCB1 Polymorphisms Don't Condition the Efficacy and Toxicity of Nilotinib As First-Line Treatment: An Italian Multicentric Experience. Blood, 2016, 128, 3951-3951.	1.4	0
143	Single shot medium dose melphalan in resistant/relapsed myeloma: a bridge to target therapies?. Trends in Transplantation, 2018, 11, .	0.2	0
144	Presentation and Outcome of 199 Patients with 2016 Who Diagnosis of Early and Overt Primary Myelofibrosis Treated with Ruxolitinib. Blood, 2018, 132, 3052-3052.	1.4	0

#	ARTICLE	IF	CITATIONS
145	Risk Factors for Progression to Blast Phase and Outcome in 589 Patients with Myelofibrosis Treated with Ruxolitinib: Real-World Evidence. <i>Blood</i> , 2019, 134, 4166-4166.	1.4	0